SCHEMBL7735518

SCHEMBL7735518

CCOC(=O)c1cccn(-c2ccc(OC)cc2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 1/20 0.56
KMT2A Q03164 1/20 0.48
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
TSHR P16473 1/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PDE4D Q08499 1/20 0.47
MAPT P10636 3/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30388175 0.85 GABRA2 (0.50) ALDH1A1HPGDKDM4EKMT2AGABRA2
SCHEMBL4994103 0.84 TSHR (0.51) ALDH1A1HPGDKDM4EKMT2AGABRA2
SCHEMBL15328181 0.81 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EKMT2ALMNA
SCHEMBL2887305 0.80 PDE4D (0.53) ALDH1A1HPGDKDM4EKMT2AGABRA2
SCHEMBL31456637 0.78 NPC1 (0.54) ALDH1A1HPGDKDM4EKMT2ATSHR
SCHEMBL16703304 0.74 KMT2A (0.73) ALDH1A1HPGDKDM4EKMT2AGABRA2
SCHEMBL30292079 0.74 KDM4E (0.59) ALDH1A1HPGDKDM4EKMT2AGABRA2
SCHEMBL1136978 0.73 ALDH1A1 (0.60) ALDH1A1KDM4EKMT2AGABRA2TSHR
SCHEMBL30854470 0.73 TSHR (0.58) ALDH1A1HPGDKDM4EKMT2ATSHR
SCHEMBL4986332 0.72 MAPT (0.51) ALDH1A1HPGDKDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK ALDH1A1 716/4885HPGD 2394/4885KDM4E 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.